Teen Obesity Treatment Study Finds a Wide Care Gap

The teen obesity treatment study found a wide gap between qualifying for treatment and receiving it. In late 2025, about 9 in 10 surgery-eligible adolescents had neither a GLP-1 prescription nor obesity surgery recorded. GLP-1 medicines copy a gut hormone involved in fullness and blood sugar.

That doesn't mean every teen needed medication or surgery. It makes access a question worth discussing with a pediatric clinician. The earlier STEP TEENS results explain the semaglutide trial behind one option; this study asks who actually received treatment.

What the teen obesity treatment study found

As of November 5, 2026, the day this article was written, Northwestern's November 2 release highlights the treatment gap. The JAMA Pediatrics research letter was published online October 5, 2026.

John Rode and colleagues examined records for 1,428,086 U.S. adolescents ages 12–19 during 2017–2025. Their surgery criteria used body mass index (BMI), a measure of weight relative to height: at least 40, or 35–under 40 with an obesity-related health condition.

Weight-loss surgery, also called metabolic and bariatric surgery, changes the stomach or digestive tract. Meeting the study's criteria doesn't decide whether an operation fits an individual teenager.

Those windows matter. The paper reports the 90.4% figure for the final quarter of 2025, at the study's end.

Quarterly GLP-1 prescribing rose from 301 to 10,676 per 100,000 eligible adolescents—a 35.5-fold increase. The medicines counted were semaglutide and liraglutide, another GLP-1 medicine.

What this means for Wegovy access

A medicine's labeled use and a family's ability to receive it are separate questions.

As of November 5, 2026, the day this article was written, the Wegovy label marked “Revised: 06/2026” includes injection treatment for obesity from age 12. It pairs treatment with a reduced-calorie diet and increased physical activity. The adolescent indication concerns obesity assessed with age- and sex-based growth charts, rather than the study's surgery cutoffs.

Younger children have a separate evidence base. The semaglutide for children guide explains that research without carrying teen findings down to a younger age.

Insurance was associated with different prescribing rates. In late 2025, privately insured adolescents had 2.4 times the GLP-1 prescribing rate of uninsured or self-pay peers. Surgery rates were similar across insurance groups. This raises questions about access, but the records don't explain each family's barriers or choices.

What the study cannot establish

The fall in surgery rates doesn't prove that medication replaced surgery. Surgery use declined 28.5% from its 2022 peak, while prescriptions rose. Changes happening together do not establish that one caused the other.

Unlike STEP TEENS, the 2022 New England Journal of Medicine trial, this study didn't assign treatment by chance. It examined existing records. It therefore doesn't compare weight change, complications, or long-term health after the two approaches.

A prescription order also doesn't show whether someone filled it or kept using the medicine. Missing records, coding errors, and care outside participating health systems can affect the counts. “Neither treatment recorded” doesn't mean “no care”: nutrition support and other treatments weren't the two outcomes counted.

Tirzepatide, another medicine used for weight management, wasn't included in the prescription count. These findings don't rank it against semaglutide for a parent's own treatment. That comparison needs evidence relevant to the person and the preparation being considered.

What a useful pediatric visit covers

For families, the practical question is whether the teenager has had a full discussion of suitable options. That includes their preferences, health conditions, growth, eating patterns, mental health, and support at home.

As of November 5, 2026, the day this article was written, the World Health Organization's October 7 guidance offers wider context. For ages 10–19, it says treatment with approved medicines may be considered only when a supervised lifestyle program hasn't achieved the desired results. Surgery may be considered under strict conditions for severe obesity. These global recommendations also emphasize mental health and long-term follow-up.

A useful conversation can cover who arranges specialist assessment, what insurance requires, and who follows the teen after treatment begins. The children's nutrition guide explains why appetite changes also deserve a nutrition plan.

Where a parent's own prescription fits

Parents considering semaglutide for themselves face another distinction. A licensed U.S. compounding pharmacy prepares and dispenses semaglutide prescribed through Promise. This is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not review compounded drugs for safety, effectiveness, or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

The access study didn't test a compounded preparation. Its prescribing trends cannot establish results for one. A parent's own follow-up discussion can also cover appetite, nutrition, side effects, and how concerns will be reviewed.

What to watch next

The next useful studies would follow health outcomes over time and ask families what prevented treatment. Comparisons also need to examine how medicines and surgery might work alongside each other, rather than assuming one has replaced the other.

For a family facing an access problem now, the unanswered question is specific: where did the care pathway stop? A referral, insurance decision, specialist assessment, and ongoing treatment are different steps. Knowing which step stalled gives the next conversation a clearer purpose.

At Promise, a licensed provider reviews every request, and not everyone qualifies.